Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
After hip or knee replacement, aspirin failed to show non-inferiority to rivaroxaban or warfarin for preventing death or symptomatic clots (1.26% vs 0.94% and 1.23%). The anticoagulants in turn did not match aspirin on safety.
RCTn = 18,883
Pellegrini et al. Prevention of Venous Thromboembolism after Total Hip or Knee ReplacementMeta-analysis of 18 mostly non-randomised studies (14,516 suspected stroke patients): bypass to a comprehensive stroke centre vs nearest centre was linked to more 90-day independence (OR 1.23) and groin puncture 64 min earlier; deaths were higher in brain haemorrhage (RR 1.30).
Meta-analysisn = 14,516
Ingwersen et al. Severity-Based Triage for Direct Transportation to Nearest Comprehensive Stroke Center: A Systematic Review and Meta-AnalysisMeta-analysis of 8 RCTs (8367 patients) with HER2-positive breast cancer: pertuzumab-based regimens improved overall survival in advanced/metastatic disease (HR 0.71) but not significantly in neoadjuvant/adjuvant settings (HR 0.81, 95% CI 0.22-3.04); adverse events similar.
Meta-analysisn = 8,367
Aboushawareb et al. Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trialsMeta-analysis of 7 randomised contrasts (2,627 participants) in non-metastatic TNBC: adding carboplatin to comparable chemotherapy improved disease control (HR 0.779) and pCR (OR 2.04), but overall survival benefit was not established (HR 0.810, p=0.107).
Meta-analysisn = 2,627
Wu et al. Survival benefit of adding carboplatin to standard anthracycline-taxane chemotherapy in triple-negative breast cancer: an updated systematic review and meta-analysisIn 2057 patients after acute coronary syndrome, a nurse-coordinated prevention programme reduced CV death, non-fatal MI or non-fatal stroke vs standard care (16.2% vs 22.6%; HR 0.70, 95% CI 0.57-0.85), mainly through fewer non-fatal MIs (9.3% vs 15.2%).
RCTn = 2,057
Magnani et al. A nurse-coordinated intervention programme vs standard of care after an acute coronary syndrome: the ALLEPRE trialSkipping ACE inhibitors or ARBs on the morning of non-cardiac surgery cut perioperative hypotension in patients aged 60 to 80 (31.2% vs 45.5%), with no rise in 30-day complications or deaths.
RCTn = 2,036
Yang et al. Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trialIn 997 adults with acute ischaemic stroke (NIHSS 7–20) treated within 48 hours in China, 10 days of IV loberamisal vs placebo raised the proportion with mRS 0–1 at 90 days (69.7% vs 56.3%; RR 1.24, 95% CI 1.12–1.36), with similar adverse event rates.
RCTn = 998
Li et al. Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical TrialSystematic review of 33 studies (970 patients; 13 neoadjuvant meta-analysed): disitamab vedotin-containing neoadjuvant regimens in localised urothelial carcinoma gave a pooled pCR rate of 48%. HER2 not clearly linked to response; grade ≥3 AEs ≤35%; no trial was blinded.
Meta-analysisn = 970
Suleja et al. Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysisIn a meta-analysis of 11 studies (648 men with imaging-suspected significant prostate cancer), radical prostatectomy without prior biopsy found significant cancer in 94.2%, benign pathology in 0.3%; overtreatment 5.7%, positive margins 25.4%. Risk of bias serious.
Meta-analysisn = 648
Anceno et al. Diagnostic yield and early outcomes of radical prostatectomy without prior histopathologic diagnosis: a single-arm systematic review and meta-analysisMeta-analysis of 2 RCTs (606 randomised, 590 analysed) in non-muscle-invasive bladder cancer: urinary biomarker-guided surveillance cut cystoscopy use by 55.8–74.9% vs standard cystoscopy, with no significant difference in recurrence (RR 1.04); non-inferiority not established.
Meta-analysisn = 606
Abushamma et al. Urinary biomarker-guided surveillance versus standard cystoscopic surveillance for non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials